These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 3126247)
21. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Meyer RD; Liu S Chemotherapy; 1986; 32(5):425-30. PubMed ID: 3093154 [TBL] [Abstract][Full Text] [Related]
22. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms. Livermore DM; Yang YJ J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657 [TBL] [Abstract][Full Text] [Related]
23. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs]. Watanabe Y; Fujiue Y; Yano S; Shimizu S; Muroki K; Doi M; Kuwabara M Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317 [TBL] [Abstract][Full Text] [Related]
24. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104 [TBL] [Abstract][Full Text] [Related]
25. Resistance to ciprofloxacin appearing during therapy. Chin NX; Clynes N; Neu HC Am J Med; 1989 Nov; 87(5A):28S-31S. PubMed ID: 2511760 [TBL] [Abstract][Full Text] [Related]
26. The role of fluoroquinolones in the promotion of alginate synthesis and antibiotic resistance in Pseudomonas aeruginosa. Piña SE; Mattingly SJ Curr Microbiol; 1997 Aug; 35(2):103-8. PubMed ID: 9216884 [TBL] [Abstract][Full Text] [Related]
27. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Daikos GL; Lolans VT; Jackson GG Antimicrob Agents Chemother; 1988 May; 32(5):785-7. PubMed ID: 3134852 [TBL] [Abstract][Full Text] [Related]
28. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Fukuda H; Hosaka M; Hirai K; Iyobe S Antimicrob Agents Chemother; 1990 Sep; 34(9):1757-61. PubMed ID: 2126688 [TBL] [Abstract][Full Text] [Related]
29. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. Gülay Z; Atay T; Amyes SG J Chemother; 2001 Oct; 13(5):546-54. PubMed ID: 11760220 [TBL] [Abstract][Full Text] [Related]
31. Genodiversity of resistant Pseudomonas aeruginosa isolates in relation to antimicrobial usage density and resistance rates in intensive care units. Jonas D; Meyer E; Schwab F; Grundmann H Infect Control Hosp Epidemiol; 2008 Apr; 29(4):350-7. PubMed ID: 18269329 [TBL] [Abstract][Full Text] [Related]
32. Instability of in vitro resistance to imipenem in Pseudomonas aeruginosa. Wolter EJ; Witte W J Basic Microbiol; 1990; 30(8):617-22. PubMed ID: 2129043 [TBL] [Abstract][Full Text] [Related]
33. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Jakics EB; Iyobe S; Hirai K; Fukuda H; Hashimoto H Antimicrob Agents Chemother; 1992 Nov; 36(11):2562-5. PubMed ID: 1489207 [TBL] [Abstract][Full Text] [Related]
34. [Comparative bactericidal activity of imipenem and other antibiotics against Pseudomonas aeruginosa]. Thabaut A; Meyran M Pathol Biol (Paris); 1988 May; 36(5):472-6. PubMed ID: 3136428 [TBL] [Abstract][Full Text] [Related]
35. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Chamberland S; Bayer AS; Schollaardt T; Wong SA; Bryan LE Antimicrob Agents Chemother; 1989 May; 33(5):624-34. PubMed ID: 2502066 [TBL] [Abstract][Full Text] [Related]
36. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates. Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550 [TBL] [Abstract][Full Text] [Related]
37. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977 [TBL] [Abstract][Full Text] [Related]
38. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates. Bassey CM; Baltch AL; Smith RP J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401 [TBL] [Abstract][Full Text] [Related]
39. Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy. Rowen RC; Mullenix TA; Arroyo JC; Voris JC Drug Intell Clin Pharm; 1988 Oct; 22(10):773-6. PubMed ID: 3147888 [TBL] [Abstract][Full Text] [Related]
40. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Hu YF; Liu CP; Wang NY; Shih SC BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]